# US 2023/0025003 A1 · Diabetes therapy targeting abnormal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0025003 A1
- Document ID: US20230025003A1
- Status: Published application
- Kind: A1
- Application number: 17/769,706
- Filed: 2020-10-16
- Published: 2023-01-26
- Earliest claimed: 2019-10-18
- Assignees: Biozipcode, Inc.
- Applicants: Biozipcode, Inc.
- Inventors: Hideto Kojima; Tomoya Terashima; Miwako Katagi
- Web page: https://patentgrep.com/patent/US20230025003A1

## CPC

- C07K 16/2836: {against CD106}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides a diabetes mellitus therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus, said therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a diagnosis of diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus or a risk of the same, said diagnosis using abnormal stem cells as an index. In one embodiment, the abnormal stem cells described in the present disclosure are abnormal hematopoietic stem cells. In one embodiment, CD106 is expressed in the abnormal stem cells described in the present disclosure at a level different from in normal cells.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A method for treating and/or preventing diabetes mellitus or a disease, disorder, and/or symptom associated with diabetes mellitus in a subject, comprising administering an effective amount of an agent that reduces or eliminates an abnormal hematopoietic stem cell (HSC) in the subject.

### Claim 14

A method for diagnosing diabetes mellitus or diabetes mellitus and/or a disease, disorder, and/or symptom associated with diabetes mellitus or a risk thereof in a subject, comprising detecting an abnormal hematopoietic stem cell (HSC) in the subject.

### Claim 15 (depends on 13)

The method of claim 13, wherein the abnormal HSC is a cell in which a gene or protein selected from the group consisting of CD106 and a functional equivalent thereof is not expressed and/or does not function at a normal level.

### Claim 16 (depends on 15)

The method of claim 15, wherein the expression which is not at a normal level is overexpression.

### Claim 17 (depends on 15)

The method of claim 15, wherein the suppressing agent comprises at least one selected from the group consisting of an anti-CD106 antibody or a functional variant thereof.

### Claim 18 (depends on 15)

The method of claim 15, further wherein the abnormal HSC is a cell in which a gene or protein selected from the group consisting of CD34, tumor necrosis factor alpha (TNF-α), histone deacetylase (HDAC), and proinsulin is not expressed at a normal level.

### Claim 19 (depends on 18)

The method of claim 18, wherein the suppressing agent comprises at least one selected from the group consisting of an anti-TNF-α antibody or a functional variant thereof and an HDAC inhibiting agent.

### Claim 20 (depends on 13)

The method of claim 13, wherein the disease, disorder, and/or symptom comprises a diabetic complication.

### Claim 21 (depends on 13)

The method of claim 13, wherein the disease, disorder, and/or symptom is selected from the group consisting of neuropathy, nephropathy, hepatopathy, retinopathy, fatty liver, gastrointestinal disorder, delayed bone fracture healing, eating disorder, and dermatopathy.

### Claim 22 (depends on 14)

The method of claim 14, wherein the abnormal HSC detection agent comprises a detection agent for CD106 or a functional equivalent.

### Claim 23 (depends on 14)

The method of claim 14, wherein the abnormal HSC detection agent comprises a detection agent for CD34, tumor necrosis factor alpha (TNF-α), histone deacetylase (HDAC), and/or proinsulin.
